InvestDashboard.com



Aratana Therapeutics, Inc. (PETX)



$4.97
52 Week Low
$6.2
2017-04-28 15:03:15 MDT
$10.73
52 Week High

Basic Info

Healthcare
Sector
Biotechnology
Industry
Nasdaq
Stock Exchange
United States
Country

Market Cap: $228,290,000Small Cap (Between $200M and $2B)
Analyst Recommendation:1.8Analysts say: Buy+. (1=Strong Buy, 5=Strong Sell)
Beta: 3.17 Higher Volatility Stock (beta over 1). Stock will go up more when the market goes up, and go down more when the market goes down. Beta of 1 means stock would match the S&P 500 Index.

Fundamentals

ForwardPE: Unknown
5 Yr Est Growth: 15.00%
Yield: 0.00%
PEG-Y Ratio: N/A
Unknown PEG-Y ratio

Technicals

% Above 50 DayMA: 10.52%
% Above 200 DayMA: -13.17%
PETX Performance 52 Weeks: -12.71%
S&P 500 Performance 52 Weeks: 13.50%
Mixed Trend. Short Term trend is up, but longer term trend is down. Currently beyond technical death cross because 50 Day MA is below 200 Day MA. Stock is closer to 52 Week Low than 52 Week High.
PETX underperforming S&P 500 by -26.21% the last 52 Weeks.

Profile

Aratana Therapeutics, Inc., incorporated on December 1, 2010, is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. The Company's lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). The Company's product candidates also include AT-014 for dogs.

More Valuation

Price To Book: 2.49
Great Value. Low Price to Book means better value.
EV to EBITDA: -8.32
Unknown EV to EBITDA ratio

More Info

Field Value Average Comments
% Held By Insiders22.37% 17.28%Held by greater than average Insiders. Insiders can sway stock price. Watch insider buying and selling.
% Held By Institutions70.00% 62.07%Institutional percentage greater than average. Institutional buying and selling can really move stock price.
Short % Of Float14.67% 07.02% Shorted by greater than average percent. Investors and traders do not believe in stock. But watch out for short squeezes pushing stock upwards.
Debt to Equity0.44 1.08 More Conservative Financing. Each industry has different Debt/Equity standard. Higher than 1 means company is taking on more leverage.
Profit Margin %-87.09%-00.18% Profit Margin is less than average.
Operating Margin %-59.34%-05.28% Operating Margin less than average percent. Stock can do better than this?
Return on Equity %-34.98%-08.79% Return on Equity less than average percent. Stock can do better than this?
Return on Assets %-9.58%-01.29% Return on Assets less than average percent. Stock can do better than this?
Revenue Per Employee $458,928.57 $883,096.70 Less than average Revenue Per Employee. This stock (or industry) might not be as efficient as others? Each industry might have a different standard.
Price to Cash 2.63 5.52 Lower than average Price to Cash. Meaning that the company has a higher percentage of cash as a percent of price. Cash can be good to cushion company during hard times, and as a potential source for buyouts or investments. However, some activists want the cash to be used by a company to buy its own stock, or to increase their dividend, or to invest the money.
CPEGY Ratio N/A 2.26Unknown.

Quick Thoughts

PROS:
  1. Analysts like this stock: 1.8 (1=Strong Buy, 5=Strong Sell)

  2. Good 5 Yr Est Growth: 15.00%

  3. Stock is Above Short Term 50DMA: 10.52%

  4. Price to Cash Ratio (2.63) is less than average. Good. Company has more cash as percentage of price than other companies.

  5. Price to Book is under 5: 2.49

  6. Debt To Equity is lower than 1: 0.44

CONS:
  1. Stock is Below Long Term 200DMA: -13.17%

  2. Stock underperforming S&P 500 over last 52 weeks: -26.21%

  3. Shorted more than average: 14.67%

  4. Profit Margin is negative: -87.09%

  5. Operating Margin is negative: -59.34%

  6. Return on Equity is negative: -34.98%

  7. Return on Assets is negative: -9.58%


Headlines


Stock Chart


InvestDashboard.com PETX: Aratana Therapeutics, Inc.

This page updated Tue May 2 22:00:01 MDT 2017.